18+ years of biotech venture investing and $3B+ in IPO/M&A outcomes. Our network sources the deals — and tells us fast whether a company needs funding or faster enrollment.
For biotechs with a real asset and no cash: our affiliate structures a funded confirmatory trial in exchange for a royalty and warrant — no extra cash cost to the company.
For funded trials stalling on recruitment: our affiliate's clinical site network delivers fast, predictable patient enrollment and centralized quality control.
Every biotech we meet has one of two problems: not enough money, or not enough patients. We route capital-constrained companies to AllianceXPartners (AXP) and enrollment-constrained ones to SMOMT.
AXP pairs each confirmatory trial with an EAEU pharma partner, opening regional rights and registration alongside the US FDA filing.
Each AXP royalty is a durable, saleable asset. Aggregators pay a premium for a diversified book — the exit template we're building toward.
AXP turns underfunded or a failed-but-salvageable late clinical stage trial into a funded confirmatory trial at no additional cash cost to the biotech — the FDA-usable data package that unlocks approval, partnership, or acquisition.